非弁膜性心房細動患者における経口抗凝固薬の安全性と有効性

基本情報

NCT ID

NCT03570047

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

73,989

治験依頼者名

Pfizer

概要

An anticoagulation therapy is a critical treatment to prevent thromboembolism in non-valvular AF (NVAF) patients. Warfarin, a vitamin K antagonist, is the first oral anticoagulant approved for the treatment for prevention of thromboembolism and it had long been the only oral anticoagulant until the first non-vitamin K antagonist oral anticoagulants (NOACs). However, its safety and effectiveness remains unknown in real-world clinical practice in Japan

対象疾患

依頼者（Sponsor）

実施施設 (1)